8-K: Albemarle Divests Ketjen Stake, Eurecat JV for $660M

Albemarle Corporation announced the sale of a controlling stake in its Ketjen refining catalyst solutions business and its 50% interest in the Eurecat joint venture, expecting $660 million in pre-tax cash proceeds.

Summary

• Albemarle Corporation is selling a controlling stake in its Ketjen refining catalyst solutions business to ChemCat AcquisitionCo, LLC, an affiliate of KPS Capital Partners LP.
• Albemarle will receive an estimated $536 million in cash from the Ketjen sale and will retain approximately a 49% interest in ChemCat Holdings, LP (Holdco), a newly formed Delaware limited partnership controlled by KPS.
• Concurrently, Albemarle is selling its entire 50% interest in the Eurecat S.A. joint venture to Axens SA for 105 million Euro (approximately $125 million USD).
• Total pre-tax cash proceeds from both transactions are expected to be approximately $660 million.
• Albemarle plans to use these proceeds for debt reduction and other general corporate purposes.
• The transactions are expected to close in the first half of 2026, subject to customary closing conditions and regulatory approvals.
• Albemarle expects to record a non-cash goodwill impairment charge of $181.5 million in the third quarter of 2025, representing the full value of goodwill associated with the Refining Solutions reporting unit as of September 30, 2025.
• The Refining Solutions reporting unit, including Albemarle's interest in Eurecat S.A., will be classified as held for sale in Albemarle's consolidated financial statements as of September 30, 2025.
• Ketjen's business post-transaction will focus on developing, manufacturing, and marketing catalysts and related products globally. Albemarle will retain 100% of Ketjen Corporation's Performance Catalyst Solutions (PCS) business.

Sentiment

Score: 5

Explanation: The strategic rationale for the divestiture, focusing the portfolio and providing significant cash for debt reduction, is positive. However, the non-cash goodwill impairment charge of $181.5 million is a notable negative financial impact. The retained 49% stake in Ketjen offers future upside, balancing the immediate negative.

Positives

• Expected total pre-tax cash proceeds of approximately $660 million from the combined transactions.
• Proceeds will be used for debt reduction and other general corporate purposes, improving financial flexibility.
• The transactions align with Albemarle's strategic priorities to focus on core businesses and competencies, and streamline operations.
• Albemarle retains an approximately 49% stake in Ketjen, indicating belief in its future earnings growth and value creation under KPS direction.
• Continued collaboration between Ketjen and Eurecat on advanced catalyst technologies and services.

Negatives

• Albemarle expects to record a non-cash goodwill impairment charge of $181.5 million in the third quarter of 2025.
• The impairment charge represents the full value of goodwill associated with the Refining Solutions reporting unit.
• Future impairment charges could occur as the disposal group is measured at the lower of its carrying amount or fair value less costs to sell.

Risks

• Failure to obtain necessary regulatory approvals or delays in obtaining them, or approvals subject to unanticipated conditions.
• Transactions may not be consummated in a timely manner.
• Albemarle may experience unanticipated delays or difficulties and transaction costs in consummating the transactions.
• Closing conditions to the transactions may not be satisfied in a timely manner or at all.
• Actual impairment charges recorded by Albemarle could be significantly greater than currently anticipated.
• Disruption from the transactions and diverting of management's attention, making it more difficult to maintain business and operational relationships.
• Failure to realize the benefits expected from the transactions or other related strategic initiatives.
• Impact of the transaction announcement and completion on Albemarle's share price and market volatility.
• Effect of the announcement on Albemarle's ability to retain customers, suppliers, key personnel, and maintain relationships with customers, suppliers, and lenders.
• Effect of the transactions on Albemarle's operating results and businesses generally.
• Possibility of more attractive strategic options arising in the future.
• Purchaser's ability to obtain the proceeds of the debt and equity financings necessary to pay the purchase price.

Future Outlook

Albemarle expects the transactions to close in the first half of 2026, pending regulatory approvals. The company anticipates using the approximately $660 million in pre-tax cash proceeds for debt reduction and other general corporate purposes, aligning with its strategic focus on core businesses and improved financial flexibility. However, it also expects to record a non-cash goodwill impairment charge of $181.5 million in Q3 2025, and future impairment charges could arise from the reclassification of the Refining Solutions reporting unit as held for sale.

Management Comments

• "We have been impressed with KPS and their proven expertise in managing large, global manufacturing and industrial businesses. Albemarle's retained stake in Ketjen highlights our belief in the business' earnings growth and value creation potential under KPS direction, and we look forward to partnering with them in driving Ketjen's next phase of growth. These transactions align with Albemarle's strategic priorities to focus on our core businesses and competencies, improve financial flexibility, and streamline operations." Kent Masters, Chairman and CEO of Albemarle.
• "We are thrilled to make a controlling investment in Ketjen and partner with Albemarle in this next phase of growth for Ketjen. We will leverage KPS' decades of global manufacturing experience to create an entrepreneurial culture centered on innovation and continuous improvement, while providing strategic support and capital to accelerate the Company's growth opportunities. We look forward to partnering with Ketjen's talented employees, senior management team and Albemarle to drive the Company's growth and profitability." Raquel Vargas Palmer, Managing Partner of KPS.
• "Our clients can expect Ketjen to continue to provide advanced FCC and HPC catalyst solutions for refinery applications, along with ongoing collaboration with Eurecat in regeneration, rejuvenation, ex-situ sulfiding, and spent catalyst processing." Michael J. Simmons, President of Ketjen.
• "Through this acquisition, Axens intends to further advance catalyst circularity and ex situ activation on all catalysts, while also initiating new initiatives focused on reducing the carbon footprint in catalyst management and activation." Quentin Debuisschert, Chairman & CEO of Axens.

Industry Context

This divestiture by Albemarle reflects a broader trend among diversified chemical and materials companies to streamline portfolios and focus on core, high-growth segments, often driven by sustainability trends (e.g., lithium for EVs). The sale of Ketjen's refining catalyst business and the Eurecat JV allows Albemarle to concentrate on its "essential elements for mobility, energy, connectivity and health" (likely referring to lithium and bromine). KPS Capital Partners' acquisition of a controlling stake in Ketjen, a global catalyst provider, indicates private equity's continued interest in industrial manufacturing assets with potential for operational improvement and growth. Axens' full acquisition of Eurecat emphasizes the growing importance of catalyst circularity and carbon footprint reduction in the refining and petrochemical industries.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the transactions against global benchmarks. A detailed assessment against industry standards cannot be provided based solely on the content of this filing.

Management Changes

Corporate Governance

Legal Proceedings

• The Stock Purchase Agreement includes a termination fee of $32.5 million payable by the Purchaser to Albemarle under certain specified circumstances, with a limited guarantee from KPS affiliates for certain payment obligations, including this fee. This implies potential legal action if the fee is not paid.
• Forward-looking statements mention risks of termination of sale agreements or failure to obtain regulatory approvals, which could lead to legal disputes.
• No material Actions or Governmental Orders are pending or threatened against the Acquired Companies or JV Entities, or against executive officers/directors in their capacity as such, since the Lookback Date.

Related Party Transactions

• The transaction creates a new related party relationship where Albemarle will hold an approximately 49% interest in ChemCat Holdings, LP (Holdco), which will control Ketjen, alongside KPS Capital Partners LP.
• The Stock Purchase Agreement details the contribution of Contributed Shares to Holdco in exchange for Rollover Equity (common units of Holdco) by Albemarle.
• A Holdco JV Agreement will be entered into by Parent, Seller (Albemarle), and the Investor (KPS affiliate) to govern the relationship and operations of Holdco.
• All existing Affiliate Agreements, including Intercompany Agreements and Intercompany Indebtedness, between Albemarle's retained entities and the divested Ketjen entities are to be paid, discharged, compromised, settled, terminated, or otherwise eliminated at or prior to the Closing, except for specific Ancillary Agreements and Shared Contracts.

Stakeholder Impact

• Shareholders (Albemarle): Expected to benefit from improved financial flexibility, debt reduction, and a more focused portfolio. The non-cash impairment charge will impact reported earnings but is not a cash outflow. Retained stake in Ketjen offers potential for future value.
• Shareholders (KPS Capital Partners): Gaining a controlling interest in Ketjen, with plans to drive growth and profitability.
• Employees (Ketjen): Transferred Employees will continue employment with Acquired Companies, with comparable compensation and benefits for 12 months post-closing. Collective Bargaining Agreements will be honored.
• Customers & Suppliers (Ketjen): Management expects continued provision of advanced catalyst solutions and collaboration with Eurecat. Risks include potential disruption to relationships due to the transaction.
• Creditors (Albemarle): Debt reduction is a positive for creditors.
• Regulatory Authorities: Approvals under HSR Act, Competition Laws, and FI Laws are required.

Next Steps

• Negotiate, execute, and deliver definitive agreements for the Debt Financing.
• Satisfy all conditions to funding for the Financing.
• Obtain all necessary regulatory approvals (HSR Act, Competition Laws, FI Laws).
• Complete consultation processes with the Dutch Works Council and European Works Council.
• Finalize the Holdco JV Agreement and other related ancillary documentation.
• Perform the PCS Restructuring, Eurecat Carveout, and General Carveout Actions.
• Close the Ketjen and Eurecat transactions in the first half of 2026.
• Albemarle to use proceeds for debt reduction and general corporate purposes.
• Purchaser to arrange replacements for Credit Support and secure unconditional release of Albemarle.
• Acquired Companies to establish new Benefit Plans for Transferred Employees.
• Acquired Companies to establish a new defined contribution retirement plan (Post-Closing DC Plan).

Key Dates

Recommendation

The transaction is strategically sound for Albemarle, focusing its portfolio and providing significant cash for debt reduction. However, the non-cash goodwill impairment charge is a notable negative. The retained 49% stake in Ketjen offers future upside, but the immediate impact of the impairment and the ongoing integration risks suggest a 'hold' position until the strategic benefits fully materialize and the new Ketjen entity demonstrates its growth trajectory under KPS. The market will likely digest the impairment alongside the strategic benefits.

Keywords

Albemarle, Ketjen, KPS Capital Partners, Eurecat, Axens SA, Catalyst Solutions, Refining Catalysts, Joint Venture, Divestiture, Goodwill Impairment, Strategic Review, Debt Reduction, Specialty Chemicals